<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6642">
  <stage>Registered</stage>
  <submitdate>20/07/2017</submitdate>
  <approvaldate>20/07/2017</approvaldate>
  <nctid>NCT03243292</nctid>
  <trial_identification>
    <studytitle>Bronchial Thermoplasty 10+ Year Study</studytitle>
    <scientifictitle>Ten Year Follow-up of Subjects From 3 Landmark Randomized Controlled Bronchial Thermoplasty (BT) Studies</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>92115848</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Asthma</healthcondition>
  </conditions>
  <interventions>
    <interventions>Other interventions - Bronchial Thermoplasty

Treated - Subjects that received Bronchial Thermoplasty in a prior study (AIR, RISA, or AIR2)

Control - Subjects that participated in prior study (AIR) or (RISA) but did not receive Bronchial Thermoplasty Treatment

Sham - Subjects that participated in the AIR2 study, were blinded and did not receive the treatment


Other interventions: Bronchial Thermoplasty
patients had radio frequency ablation of the smooth muscle for asthma

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary Safety Endpoint - Absence of bronchiectasis or bronchial stenosis</outcome>
      <timepoint>1 visit within 30 days of enrollment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Primary Effectiveness Endpoint - Number of subjects who experience severe asthma exacerbations during the first and fifth years after treatment with the proportion of subjects who experience severe asthma exacerbations 12 months prior to enrollment.</outcome>
      <timepoint>1 visit within 30 days of enrollment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Severe asthma exacerbation rates exacerbations - evaluated for the 12 month period prior to the BT 10+ study visit and will be compared to the first and fifth years after BT treatment:</outcome>
      <timepoint>One day visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Severe asthma exacerbation rates subject - evaluated for the 12 month period prior to the BT 10+ study visit and will be compared to the first and fifth years after BT treatment:</outcome>
      <timepoint>One day visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Severe asthma exacerbation rates year - evaluated for the 12 month period prior to the BT 10+ study visit and will be compared to the first and fifth years after BT treatment:</outcome>
      <timepoint>One day visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>rates of emergency room visits for respiratory adverse events - evaluated for the 12 month period prior to the BT 10+ study visit and will be compared to the first and fifth years after BT treatment:</outcome>
      <timepoint>One day visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>proportion of subjects with emergency room visits for respiratory adverse events - evaluated for the 12 month period prior to the BT 10+ study visit and will be compared to the first and fifth years after BT treatment:</outcome>
      <timepoint>One day visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rates of hospitalizations for respiratory adverse events - evaluated for the 12 month period prior to the BT 10+ study visit and will be compared to the first and fifth years after BT treatment:</outcome>
      <timepoint>One day visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with hospitalizations for respiratory adverse events - evaluated for the 12 month period prior to the BT 10+ study visit and will be compared to the first and fifth years after BT treatment:</outcome>
      <timepoint>One day visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rates of Respiratory Serious Adverse Events (SAEs) - evaluated for the 12 month period prior to the BT 10+ study visit and will be compared to the first and fifth years after BT treatment:</outcome>
      <timepoint>One day visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with respiratory SAEs) - evaluated for the 12 month period prior to the BT 10+ study visit and will be compared to the first and fifth years after BT treatment:</outcome>
      <timepoint>One day visit</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion Criteria

          -  Subjects previously enrolled in AIR, RISA or AIR2

          -  Subjects who received active BT treatment and had last BT treatment at least 10 years
             and 6 weeks prior to enrollment

          -  Control/Sham subjects with at least 10 years of long-term follow-up from index date
             plus 6 weeks

          -  Subject is able to read, understand and sign a written Informed Consent to participate
             in the Study and able to comply with the study requirements</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Severe asthma exacerbation or chest infection in the past 4 weeks. Subject entry into
             this study should be delayed until free from severe asthma exacerbation or chest
             infection for a minimum of 4 weeks.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/10/2017</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>196</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/10/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <postcode>5000 - Adelaide</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>RS</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>PÃ´rto Alegre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Groningen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Scotland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leicester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Boston Scientific Corporation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To confirm the long-term efficacy and safety of Bronchial Thermoplasty (BT) at 10 years
      follow-up or beyond in subjects previously enrolled in any of the following Boston
      Scientific-sponsored, controlled pre-approval studies: AIR, RISA and AIR2.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03243292</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Frances Nolan, BSN</name>
      <address />
      <phone>216-233-4467</phone>
      <fax />
      <email>frances.nolan@bsci.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>